Bora Pharmaceuticals Co., LTD. (TPE:6472)
Taiwan
· Delayed Price · Currency is TWD 675.00
-46.00 (-6.38%)
Mar 31, 2025, 1:30 PM CST
TPE:6472 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 19,246 | 14,200 | 10,494 | 4,900 | 1,800 | Upgrade
|
| Revenue Growth (YoY) | 35.53% | 35.31% | 114.18% | 172.28% | 17.68% | Upgrade
|
| Cost of Revenue | 11,536 | 7,209 | 7,582 | 3,228 | 1,096 | Upgrade
|
| Gross Profit | 7,710 | 6,991 | 2,913 | 1,672 | 703.88 | Upgrade
|
| Selling, General & Admin | 3,633 | 1,444 | 861.52 | 584.52 | 441.16 | Upgrade
|
| Research & Development | 694.49 | 298.16 | 129.08 | 41.27 | 36.65 | Upgrade
|
| Operating Expenses | 4,328 | 1,742 | 990.6 | 625.79 | 477.81 | Upgrade
|
| Operating Income | 3,383 | 5,249 | 1,922 | 1,046 | 226.08 | Upgrade
|
| Interest Expense | -479.72 | -171.24 | -108.73 | -53.62 | -21.97 | Upgrade
|
| Interest & Investment Income | 91.42 | 62.95 | 11.36 | 0.22 | 0.96 | Upgrade
|
| Earnings From Equity Investments | -0.04 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 163.52 | -67.51 | 47.92 | -14.41 | -11.91 | Upgrade
|
| Other Non Operating Income (Expenses) | 64.53 | 39.98 | 17.41 | 48.02 | 14.28 | Upgrade
|
| EBT Excluding Unusual Items | 3,222 | 5,113 | 1,890 | 1,026 | 207.43 | Upgrade
|
| Gain (Loss) on Sale of Investments | 11.56 | -1,044 | -47.79 | - | 0.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | -27.99 | -5 | -2.36 | -2.24 | -0 | Upgrade
|
| Other Unusual Items | 1,749 | - | - | - | 387.86 | Upgrade
|
| Pretax Income | 4,955 | 4,064 | 1,840 | 1,024 | 595.4 | Upgrade
|
| Income Tax Expense | 914.58 | 992.23 | 438.48 | 274.23 | 16.97 | Upgrade
|
| Earnings From Continuing Operations | 4,040 | 3,072 | 1,402 | 749.74 | 578.43 | Upgrade
|
| Minority Interest in Earnings | -101.39 | -41.78 | -9.61 | - | - | Upgrade
|
| Net Income | 3,939 | 3,030 | 1,392 | 749.74 | 578.43 | Upgrade
|
| Net Income to Common | 3,939 | 3,030 | 1,392 | 749.74 | 578.43 | Upgrade
|
| Net Income Growth | 29.99% | 117.70% | 85.65% | 29.62% | 89.63% | Upgrade
|
| Shares Outstanding (Basic) | 102 | 100 | 98 | 97 | 96 | Upgrade
|
| Shares Outstanding (Diluted) | 112 | 104 | 99 | 97 | 97 | Upgrade
|
| Shares Change (YoY) | 8.17% | 4.93% | 1.41% | 0.86% | 7.55% | Upgrade
|
| EPS (Basic) | 38.69 | 30.20 | 14.26 | 7.73 | 6.04 | Upgrade
|
| EPS (Diluted) | 35.82 | 29.39 | 14.13 | 7.71 | 6.00 | Upgrade
|
| EPS Growth | 21.90% | 107.94% | 83.40% | 28.53% | 76.28% | Upgrade
|
| Free Cash Flow | 452.71 | 4,316 | 1,815 | 1,073 | 28.56 | Upgrade
|
| Free Cash Flow Per Share | 4.04 | 41.68 | 18.39 | 11.03 | 0.30 | Upgrade
|
| Dividend Per Share | 14.000 | 12.000 | 6.159 | 2.449 | 1.123 | Upgrade
|
| Dividend Growth | 16.67% | 94.84% | 151.52% | 118.15% | 29.99% | Upgrade
|
| Gross Margin | 40.06% | 49.23% | 27.76% | 34.12% | 39.11% | Upgrade
|
| Operating Margin | 17.58% | 36.97% | 18.32% | 21.35% | 12.56% | Upgrade
|
| Profit Margin | 20.47% | 21.34% | 13.26% | 15.30% | 32.14% | Upgrade
|
| Free Cash Flow Margin | 2.35% | 30.39% | 17.30% | 21.90% | 1.59% | Upgrade
|
| EBITDA | 4,240 | 5,734 | 2,169 | 1,211 | 354.25 | Upgrade
|
| EBITDA Margin | 22.03% | 40.38% | 20.67% | 24.72% | 19.68% | Upgrade
|
| D&A For EBITDA | 857.49 | 485.11 | 246.69 | 165.27 | 128.17 | Upgrade
|
| EBIT | 3,383 | 5,249 | 1,922 | 1,046 | 226.08 | Upgrade
|
| EBIT Margin | 17.58% | 36.97% | 18.32% | 21.35% | 12.56% | Upgrade
|
| Effective Tax Rate | 18.46% | 24.41% | 23.83% | 26.78% | 2.85% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.